Royal Bank Of Canada Upgrades Medpace (NASDAQ:MEDP) to Moderate Buy

Medpace (NASDAQ:MEDP) was upgraded by stock analysts at Royal Bank Of Canada to a “moderate buy” rating in a report issued on Monday,Zacks.com reports.

A number of other brokerages have also commented on MEDP. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and decreased their price objective for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a report on Friday, February 13th. Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective on the stock in a research note on Tuesday, February 10th. Finally, Truist Financial cut their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Five analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $486.67.

Medpace Trading Up 1.7%

Shares of MEDP stock opened at $465.38 on Monday. The firm has a fifty day simple moving average of $540.05 and a two-hundred day simple moving average of $539.37. Medpace has a 12 month low of $250.05 and a 12 month high of $628.92. The firm has a market capitalization of $13.21 billion, a PE ratio of 30.42, a price-to-earnings-growth ratio of 2.19 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same period last year, the firm earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts predict that Medpace will post 12.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MEDP. AQR Capital Management LLC increased its holdings in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after acquiring an additional 404,226 shares during the last quarter. Norges Bank bought a new stake in Medpace during the 2nd quarter valued at $66,597,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after acquiring an additional 211,411 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Medpace by 158.6% in the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after acquiring an additional 183,645 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in shares of Medpace by 92.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after purchasing an additional 166,654 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.